CLIN CANCER RES:miR-34a调节三阴性乳腺癌生长和侵袭

2018-09-13 MedSci MedSci原创

近期研究表明非编码RNA(ncRNA)如miRNAs与多种肿瘤的发生有关。但是miR-34a在三阴性乳腺癌中的分子机制尚不明确。CLIN CANCER RES近期发表了一篇文章研究这一问题。

近期研究表明非编码RNA(ncRNA)如miRNAs与多种肿瘤的发生有关。但是miR-34a在三阴性乳腺癌中的分子机制尚不明确。CLIN CANCER RES近期发表了一篇文章研究这一问题。

作者在体外使用三阴性乳腺癌细胞系进行功能实验研究miR-34a对FOXM1/eEF2k信号轴的影响。使用三阴性乳腺癌异种移植模型在体内研究miR-34a的治疗效果。研究结果表明,miR-34a与三阴性乳腺癌患者生存改善正相关且与致癌性eEF2K水平负相关,eEF2K与患者总生存较差有关。miR-34a可以与eEF2K和FOXM1的mRNA直接结合并抑制他们的表达,从而抑制三阴性乳腺癌细胞增殖,活动和侵袭。miR-34a表达可以抑制eEF2K和FOXM1,而过表达eEF2K和FOXM1则会逆转miR-34a介导的效果及信号通路。体内实验中,通过静脉输入治疗性miR-34a纳米药物可以抑制eEF2K和FOXM1,瘤内增殖及血管生成,诱导肿瘤细胞凋亡,从而抑制肿瘤生长。

文章最后认为,该研究为miR-34a对FOXM1/eEF2K通路的影响提供了新的方向,miR-34a基因治疗可以作为三阴性乳腺癌的潜在治疗方式。

原始出处:
Recep Bayraktar,Cristina Ivan,et al.Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple Negative Breast Cancer Growth and Invasion.CLIN CANCER RES.September 2018 doi:10.1158/1078-0432.CCR-17-1959

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2047993, encodeId=6790204e99351, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Sun Sep 30 11:25:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943500, encodeId=6773194350046, content=<a href='/topic/show?id=0fa31188829' target=_blank style='color:#2F92EE;'>#miR-34a#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11888, encryptionId=0fa31188829, topicName=miR-34a)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Thu Oct 11 01:25:00 CST 2018, time=2018-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930647, encodeId=6266193064e2c, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Sat May 04 19:25:00 CST 2019, time=2019-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458714, encodeId=e2f81458e1418, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19820, encryptionId=3ef91982030, topicName=三阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5666112721, createdName=xlysu, createdTime=Sat Sep 15 11:25:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=344949, encodeId=a68f344949fc, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Fri Sep 14 08:52:28 CST 2018, time=2018-09-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2047993, encodeId=6790204e99351, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Sun Sep 30 11:25:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943500, encodeId=6773194350046, content=<a href='/topic/show?id=0fa31188829' target=_blank style='color:#2F92EE;'>#miR-34a#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11888, encryptionId=0fa31188829, topicName=miR-34a)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Thu Oct 11 01:25:00 CST 2018, time=2018-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930647, encodeId=6266193064e2c, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Sat May 04 19:25:00 CST 2019, time=2019-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458714, encodeId=e2f81458e1418, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19820, encryptionId=3ef91982030, topicName=三阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5666112721, createdName=xlysu, createdTime=Sat Sep 15 11:25:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=344949, encodeId=a68f344949fc, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Fri Sep 14 08:52:28 CST 2018, time=2018-09-14, status=1, ipAttribution=)]
    2018-10-11 xzw113
  3. [GetPortalCommentsPageByObjectIdResponse(id=2047993, encodeId=6790204e99351, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Sun Sep 30 11:25:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943500, encodeId=6773194350046, content=<a href='/topic/show?id=0fa31188829' target=_blank style='color:#2F92EE;'>#miR-34a#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11888, encryptionId=0fa31188829, topicName=miR-34a)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Thu Oct 11 01:25:00 CST 2018, time=2018-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930647, encodeId=6266193064e2c, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Sat May 04 19:25:00 CST 2019, time=2019-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458714, encodeId=e2f81458e1418, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19820, encryptionId=3ef91982030, topicName=三阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5666112721, createdName=xlysu, createdTime=Sat Sep 15 11:25:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=344949, encodeId=a68f344949fc, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Fri Sep 14 08:52:28 CST 2018, time=2018-09-14, status=1, ipAttribution=)]
    2019-05-04 smallant2002
  4. [GetPortalCommentsPageByObjectIdResponse(id=2047993, encodeId=6790204e99351, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Sun Sep 30 11:25:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943500, encodeId=6773194350046, content=<a href='/topic/show?id=0fa31188829' target=_blank style='color:#2F92EE;'>#miR-34a#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11888, encryptionId=0fa31188829, topicName=miR-34a)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Thu Oct 11 01:25:00 CST 2018, time=2018-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930647, encodeId=6266193064e2c, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Sat May 04 19:25:00 CST 2019, time=2019-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458714, encodeId=e2f81458e1418, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19820, encryptionId=3ef91982030, topicName=三阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5666112721, createdName=xlysu, createdTime=Sat Sep 15 11:25:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=344949, encodeId=a68f344949fc, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Fri Sep 14 08:52:28 CST 2018, time=2018-09-14, status=1, ipAttribution=)]
    2018-09-15 xlysu
  5. [GetPortalCommentsPageByObjectIdResponse(id=2047993, encodeId=6790204e99351, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Sun Sep 30 11:25:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943500, encodeId=6773194350046, content=<a href='/topic/show?id=0fa31188829' target=_blank style='color:#2F92EE;'>#miR-34a#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11888, encryptionId=0fa31188829, topicName=miR-34a)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Thu Oct 11 01:25:00 CST 2018, time=2018-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930647, encodeId=6266193064e2c, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Sat May 04 19:25:00 CST 2019, time=2019-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458714, encodeId=e2f81458e1418, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19820, encryptionId=3ef91982030, topicName=三阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5666112721, createdName=xlysu, createdTime=Sat Sep 15 11:25:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=344949, encodeId=a68f344949fc, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Fri Sep 14 08:52:28 CST 2018, time=2018-09-14, status=1, ipAttribution=)]
    2018-09-14 kafei

    学习了谢谢

    0

相关资讯

Nat Commun:研究发现三阴性乳腺癌治疗新靶标

中科院上海生命科学研究院(营养与健康院)詹丽杏研究组分析了三阴性乳腺癌(TNBC)患者的转录组特征,发现并确认了乳腺癌中JAK2/STAT3信号的新抑制子Wwox蛋白,阐明Wwox的异常减弱和JAK2/STAT3的异常激活这样的负相关关系是高度恶性TNBC发生转移的重要原因。研究成果近日在线发表于《自然—通讯》。

CLIN CANCER RES:新辅助卡铂和多西他赛治疗的三阴性乳腺癌患者的病理缓解情况

三阴性乳腺癌(TNBC)需要可靠的能够预测新辅助化疗(NACT)反应的预测标志物。CLIN CANCER RES近期发表了一篇文章,评估TNBCtype-4分类在接受新辅助卡铂和多西他赛(Tcb)治疗的三阴性乳腺癌患者中预测治疗反应的能力。

Nat Med:“靶向化疗”成为可能—卡铂用于治疗BRCA1/2突变及BRCAness表型三阴性乳腺癌的III期TNT研究

BRCA1/2突变胚系突变在TNBC中的检出率约为10%,BRCA突变细胞对铂类药物具有很高的敏感性。在早期的新辅助研究中,发现铂类单药能使BRCA突变乳腺癌的pCR率提高到60%以上;TBCRC009研究亦显示了其在BRCA突变的晚期乳腺癌中的作用。但尚缺乏大型临床试验对其进行验证。TNT研究作为一项对比卡铂与多西他赛在BRCA1/2突变及BRCAness表型三阴性乳腺癌患者中的有效性研究,填补

ANN ONCOL:蛋白结合型紫杉醇联合卡铂或吉西他滨治疗转移性三阴性乳腺癌

转移性三阴性乳腺癌侵袭性强,往往预后较差。tnAcity试验评估了蛋白结合型紫杉醇联合卡铂(nab-P/C),蛋白结合型紫杉醇联合吉西他滨(nab-P/G)和吉西他滨联合卡铂(G/C)作为一线疗法治疗转移性三阴性乳腺癌患者的安全性和有效性。

Signal Transduct Target Ther:靶向MUC1-C可抑制三阴性乳腺癌中的BCL2A1

B细胞淋巴瘤2相关蛋白A1(BCL2A1)是抗细胞凋亡蛋白BCL-2家族的成员,是导致抗癌药物治疗抗性的主要因素,但是目前还没有针对BCL2A1的药物。MUC1-C癌蛋白在三阴性乳腺癌(TNBCs)细胞中异常表达,诱导上皮-间质转化(EMT)并促进抗癌药物抗性。本研究表明,在TNBCs细胞中靶向MUC1-C可导致BCL2A1表达的下调。结果显示,MUC1-C通过NF-κBp65介导的机制激活BCL

Cancer Cell:重磅!三阴性乳腺癌根源现世!这个基因是罪魁祸首!

目前,科学家仍对三阴性乳腺癌(triple negative breast cancer, TNBC)束手无策,其预后极差、死亡率极高,传统疗法收效甚微,是乳腺癌中恶性程度最高的亚型之一。在多方疗法尝试受阻后,研究人员转而试图探寻TNBC发病根源,进而在根源上阻断肿瘤的发生。近日,美国Salk实验室的Geoffrey Wahl教授等人在著名学术期刊《Cancer Cell》发表的一篇文章描述了TN